Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 620

Results For "AP"

8349 News Found

AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India
News | September 05, 2022

AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India

This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.


Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
Clinical Trials | September 05, 2022

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma


NATCO Pharma to sell stake in Nativita and assets of Pharma division
News | September 02, 2022

NATCO Pharma to sell stake in Nativita and assets of Pharma division

NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord


Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility
News | September 02, 2022

Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility

The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers


US FDA issues 17 observations for Biocon Biologics sites
News | September 01, 2022

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools


Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | September 01, 2022

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise


Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
Clinical Trials | September 01, 2022

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan


Bayer showcases cancer study data at ESMO Congress 2022
News | September 01, 2022

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors


A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
Healthcare | September 01, 2022

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Clinical Trials | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke